Newswise — While treatment with radioactive iodine (RAI) after surgery for thyroid cancer is a standard of care, R. Michael Tuttle, M.D., professor of medicine at Memorial Sloan Kettering Cancer Center in New York City, asks: “How do we know if additional RAI is likely to produce significant clinical benefit?” Or, “How do we know when to stop treating with RAI?”
